Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Single-Centre Study to Assess the Pharmacokinetics of R406 in Healthy Volunteers When Fostamatinib Disodium 150 mg is Administered Alone and in Combination With Verapamil.

Next Previous
Search
Trial Profile

An Open-label, Single-Centre Study to Assess the Pharmacokinetics of R406 in Healthy Volunteers When Fostamatinib Disodium 150 mg is Administered Alone and in Combination With Verapamil.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fostamatinib (Primary) ; Verapamil (Primary)
  • Indications Angina pectoris; Arrhythmias; B-cell lymphoma; Chronic lymphocytic leukaemia; Hypertension; Rheumatoid arthritis; Solid tumours; T-cell lymphoma; Type 1 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca

    • Most Recent Events

    • 06 Jan 2016 Results of this and other two phase I studies published in the Drugs in R and D
    • 22 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Oct 2010 Actual initiation date added to 1 Sep 2010 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top